查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088605

醫療保健製藥合約開發和生產組織 (CMO) 市場：按服務類型、分子類型、劑型、應用、治療領域和最終用戶分類——2026-2032 年全球市場預測

Healthcare Contract Development & Manufacturing Organization Market by Service Offering, Molecule Type, Dosage Form, Application, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫療保健合約開發和生產組織 (CDMO) 市場將成長至 6,688 億美元，複合年成長率為 9.23%。

主要市場統計數據
基準年 2025 3603.8億美元
預計年份：2026年 3917.7億美元
預測年份 2032 6688億美元
複合年成長率 (%) 9.23%

醫療保健CDMO執行摘要

醫療保健產業的合約研發生產機構（CDMO）正逐漸成為製藥、生物技術、細胞和基因治療、疫苗以及醫療設備公司的戰略基礎設施。推動這一行業發展的因素包括可衡量的需求變化，例如專利到期、生物製藥的成長、複雜的無菌生產需求、供應鏈多元化以及監管機構對「品質源於設計」理念的持續重視。

CDMO產業的變革性變化

醫療保健CDMO產業正從簡單的外包模式轉向涵蓋研發、生產、包裝和生命週期管理的一體化夥伴關係。隨著對無菌注射劑、高活性藥物原料藥、生物製藥、生物相似藥、mRNA平台和先進處方藥的需求不斷成長，經驗豐富的供應商由於這些領域的技術壁壘和嚴格的監管審查而擁有顯著優勢。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在改變合約研發生產企業 (CDMO) 在配方篩檢、製程開發、預測性維護、偏差分析、視覺檢測、需求預測和法規文件等領域創造價值的方式。最具前景的應用案例是將 AI 與檢驗的資料管道、電子批次記錄 (EBR)、實驗室資訊管理系統 (LIMS)、生產執行系統 (MES) 和品管系統 (QMS) 結合。

對關鍵區域的洞察

以中國、印度、日本、韓國、新加坡和澳洲為首的亞太地區正迅速發展成為研發和生產中心，在原料藥、學名藥、生物製藥、生物相似藥、疫苗和臨床試驗用藥的供應方面擁有顯著優勢。該地區受益於成熟的活性成分生態系統、不斷成長的國內醫療保健需求、政府主導的生命科學領域投資以及國際GMP標準的日益普及。北美地區憑藉接近性FDA的地理優勢、先進的生物製藥基礎設施、創業投資驅動的生物技術需求、強大的知識產權保護以及在無菌灌裝和包裝、細胞療法、基因療法和複雜製藥及醫療設備複合物方面的深厚專業知識，仍然是領先的CDMO（合約研發機構）地區。

對主要經濟和戰略集團的洞察

東協正加強其在藥品包裝、臨床試驗藥物供應和在地化生產方面的作用，這得益於新加坡的製造地以及印尼、泰國、越南、馬來西亞和菲律賓不斷成長的醫療保健需求。該地區也受益於監管合作、不斷擴大的醫院網路以及對價格合理的學名藥和專科藥品日益成長的需求。在海灣合作理事會（GCC）國家，藥品安全和在地化生產是優先事項，產業政策、醫療保健現代化以及採購在地化，尤其是在沙烏地阿拉伯和阿拉伯聯合大公國，正在促進藥品製造領域的夥伴關係。

主要國家的概況

美國透過生物技術創新、FDA監管下的商業化、強勁的資本市場以及對生技藥品、無菌注射劑、細胞療法、基因療法和複雜學名藥的巨大需求，推動了對先進CDMO服務的需求。加拿大透過對生物製造韌性的公共投資和研發密集生命科學基礎設施，支持生物製藥、疫苗、放射性藥物和臨床階段藥物的開發。另一方面，墨西哥則受益於近岸外包、具競爭力的製造成本以及與美國供應鏈的接近性。巴西憑藉其受ANVISA監管的生產規模、國內對學名藥的需求、疫苗生產能力以及大規模的公共醫療保健系統，成為拉丁美洲的製藥中心。

為行業領導者提供的實用建議

行業領導者應優先考慮韌性和品質主導成長。建議採取的措施包括：為關鍵原料選擇替代供應商、投資無菌和生物製藥生產能力、加強技術轉移管治，以及使業務運營符合ICH Q9 (R1)、Q10、Q12、Q13和新興人工智慧相關監管要求。

調查方法

本執行摘要基於二手研究，參考了公開的監管、政策、科學和行業資訊來源，包括美國食品藥品監督管理局 (FDA)、歐洲藥品管理局 (EMA)、英國藥品和保健產品監管署 (MHRA)、世界衛生組織 (WHO)、國際人用藥品註冊技術協調會 (ICH)、經濟合作暨發展組織 (OECD)、各國衛生機構、公共研究文件申請文件、醫學文獻、研究本分析重點檢驗的結構性指標，例如生產能力、法律規範、檢查要求、供應鏈趨勢、治療方式要求和已記錄的政策優先事項。

結論

醫療保健CDMO市場正步入一個更具策略性的階段，其特點是技術複雜性、品質要求、區域多元化和數位轉型。委託企業依賴CDMO不僅是為了減少固定生產投資，也是為了獲得專業知識、縮短研發週期、獲得監管合規的支持，並確保供應的連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：醫療保健藥品合約開發和生產組織 (CMO) 市場：按服務類型分類

  • 合約開發服務
    • 臨床開發
      • 臨床試驗支持
      • 監理合規支持
    • 臨床前開發
      • 體外和體內研究
      • 毒性測試
    • 製程開發
  • 契約製造服務
    • API生產
    • 成品劑型生產（FDF）
    • 醫療設備製造
    • 包裝和標籤

第8章：醫療保健藥品合約開發和生產組織 (CMO) 市場：按分子類型分類

  • 聚合物化合物
    • 單株抗體
    • 重組蛋白
    • 疫苗
  • 低分子化合物

第9章：醫療保健藥品合約研發生產力組織（CMO）市場：按劑型分類

  • 液體
  • 半固態製劑
  • 固態劑型

第10章：醫療保健藥品合約開發與生產組織 (CMO) 市場：按應用領域分類

  • 學名藥
  • 醫療器材
  • 專利藥品

第11章：醫療保健藥品合約開發和生產組織 (CMO) 市場：按治療領域分類

  • 循環系統
  • 免疫學
  • 感染疾病
  • 代謝性疾病
  • 神經病學
  • 腫瘤學

第12章：醫療保健藥品合約開發和生產組織 (CMO) 市場：按最終用戶分類

  • 學術和研究機構
  • 生技公司
  • 學名藥生產商
  • 醫療設備製造商
  • 製藥公司
    • 大型製藥企業
    • 中小型製藥公司

第13章：醫療保健藥品合約開發與生產組織（CMO）市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：醫療保健藥品合約開發和生產組織 (CMO) 市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：醫療保健藥品合約開發與生產組織（CMO）市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent Inc.
  • Charles River Laboratories International, Inc.
  • Corden Pharma International GmbH
  • Curia Global, Inc.
  • Eurofins Scientific SE
  • EVER company group
  • Evonik Industries AG
  • FUJIFILM Diosynth Biotechnologies
  • Jabil, Inc.
  • Lonza Group AG
  • MedPharm Ltd.
  • Merck KGaA
  • NextPharma GmbH
  • Piramal Group
  • Porton Pharma Solutions Ltd
  • Recipharm AB
  • Samsung Biologics
  • Sanmina Corporation
  • Siegfried Holding AG
  • Siegfried-Group
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec
Product Code: MRR-B812DD5799E8

The Healthcare Contract Development & Manufacturing Organization Market is projected to grow by USD 668.80 billion at a CAGR of 9.23% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 360.38 billion
Estimated Year [2026] USD 391.77 billion
Forecast Year [2032] USD 668.80 billion
CAGR (%) 9.23%

Healthcare CDMO Executive Summary

Healthcare contract development and manufacturing organizations are becoming strategic infrastructure for pharmaceutical, biotechnology, cell and gene therapy, vaccine, and medical device companies. The sector is supported by measurable demand drivers, including patent expirations, biologics growth, complex sterile manufacturing needs, supply chain diversification, and continued regulatory emphasis on quality-by-design.

CDMOs now compete on more than capacity. Sponsors increasingly evaluate partners by FDA, EMA, MHRA, PMDA, and WHO-aligned compliance records; technology transfer discipline; data integrity; containment capability; cold-chain readiness; and the ability to scale from clinical batches to commercial supply without compromising current good manufacturing practice standards.

Transformative Shifts in the CDMO Landscape

The healthcare CDMO landscape is shifting from transactional outsourcing to integrated development, manufacturing, packaging, and lifecycle management partnerships. Demand is rising for sterile injectables, high-potency active pharmaceutical ingredients, biologics, biosimilars, mRNA platforms, and advanced therapy medicinal products, where technical barriers and regulatory scrutiny favor experienced operators.

At the same time, sponsors are redesigning supply networks after pandemic-era disruptions, inflationary pressure, energy cost volatility, and geopolitical risk exposure. Dual sourcing, regionalized manufacturing, validated backup capacity, and stronger supplier qualification have become board-level priorities, especially for essential medicines, critical APIs, and temperature-sensitive biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is reshaping CDMO value creation across formulation screening, process development, predictive maintenance, deviation analysis, visual inspection, demand forecasting, and regulatory documentation. The strongest use cases are emerging where AI is paired with validated data pipelines, electronic batch records, laboratory information management systems, manufacturing execution systems, and quality management systems.

Regulators have not lowered expectations for control, traceability, or human accountability. FDA, EMA, and ICH quality frameworks continue to require data integrity, explainability, risk management, and documented validation. For CDMOs, AI advantage depends on governed implementation, model monitoring, cybersecurity controls, and audit-ready documentation rather than experimental automation alone.

Key Regional Insights

Asia-Pacific is expanding as a development and manufacturing hub, led by China, India, Japan, South Korea, Singapore, and Australia, with strengths in APIs, generics, biologics, biosimilars, vaccines, and clinical trial supply. The region benefits from established active ingredient ecosystems, growing domestic healthcare demand, government-backed life sciences investment, and rising adoption of international GMP standards. North America remains a premium CDMO region because of FDA proximity, advanced biologics infrastructure, venture-backed biotechnology demand, strong intellectual property protection, and deep capabilities in sterile fill-finish, cell therapy, gene therapy, and complex drug-device combinations.

Europe benefits from EMA coordination, mature GMP systems, high-value sterile and biologics manufacturing, and strong specialty pharmaceutical clusters across Western and Central Europe. Latin America is gaining relevance through Brazil and Mexico, where regulated pharmaceutical production, public health procurement, and nearshoring dynamics support regional CDMO activity. The Middle East is investing in localization through Saudi Arabia and the UAE, with national strategies focused on medicine security, technology transfer, and domestic pharmaceutical production. Africa is at an earlier stage, supported by vaccine manufacturing initiatives, the African Medicines Agency, and AfCFTA-enabled regional integration designed to improve access, harmonize regulation, and reduce dependence on imported essential medicines.

Key Economic & Strategic Group Insights

ASEAN is strengthening its role in pharmaceutical packaging, clinical supply, and regional manufacturing, supported by Singapore's biomanufacturing base and growing healthcare demand across Indonesia, Thailand, Vietnam, Malaysia, and the Philippines. The group is also benefiting from regulatory cooperation efforts, expanding hospital networks, and demand for affordable generics and specialty medicines. The GCC is prioritizing medicine security and local production, particularly in Saudi Arabia and the UAE, where industrial policy, healthcare modernization, and procurement localization are encouraging pharmaceutical manufacturing partnerships.

The European Union remains a leading quality and regulatory reference market, supported by harmonized medicinal product oversight, advanced pharmacovigilance systems, and high GMP expectations. BRICS countries offer scale, API depth, vaccine experience, and fast-expanding healthcare consumption, with China and India particularly important to global pharmaceutical supply chains. G7 markets continue to dominate high-value innovation outsourcing because of advanced R&D ecosystems, mature regulators, and demand for complex biologics, sterile products, and advanced therapies. NATO economies add resilience considerations, as defense preparedness, secure supply chains, stockpiling policies, and essential medicine availability increasingly intersect with healthcare manufacturing strategy.

Key Country Insights

The United States leads demand for advanced CDMO services through biotechnology innovation, FDA-regulated commercialization, strong capital markets, and significant demand for biologics, sterile injectables, cell therapies, gene therapies, and complex generics. Canada supports biologics, vaccines, radiopharmaceuticals, and clinical-stage development through public investment in biomanufacturing resilience and a research-intensive life sciences base, while Mexico benefits from nearshoring, competitive manufacturing economics, and proximity to U.S. supply chains. Brazil anchors Latin American pharmaceutical manufacturing through ANVISA-regulated scale, domestic generic demand, vaccine capabilities, and a large public healthcare system.

The United Kingdom, Germany, France, Italy, and Spain remain important European CDMO markets, supported by MHRA and EMA-aligned quality expectations, skilled scientific workforces, and established pharmaceutical manufacturing clusters. Germany and France are especially strong in pharmaceuticals, specialty manufacturing, injectables, and bioprocessing, while Italy and Spain provide mature contract manufacturing, packaging, and finished-dose capabilities. Russia maintains domestic pharmaceutical production priorities driven by import substitution and medicine security policies, though sanctions and supply restrictions influence technology access and cross-border partnerships. China and India provide major API, generics, biosimilars, and biologics capacity, with China emphasizing integrated innovation and India retaining global strength in cost-efficient development and regulated generics. Japan emphasizes quality, specialty innovation, and PMDA-aligned compliance; South Korea is a global biologics manufacturing leader with strong biosimilar and bioprocessing capabilities; and Australia supports clinical trials, early development, vaccines, and Asia-Pacific regulatory bridging through strong healthcare infrastructure and internationally recognized research standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resilient, quality-led growth. Recommended actions include qualifying dual suppliers for critical materials, investing in sterile and biologics capacity, strengthening technology transfer governance, and aligning operations with ICH Q9(R1), Q10, Q12, Q13, and emerging AI-related regulatory expectations.

CDMOs should also build differentiated capabilities in high-potency manufacturing, aseptic processing, single-use bioprocessing, advanced analytics, serialization, cold-chain logistics, and sustainability reporting. Sponsors should select partners through risk-based scorecards that evaluate inspection history, data integrity, digital maturity, scalability, financial stability, cybersecurity posture, environmental controls, and demonstrated performance in comparable products.

Research Methodology

This executive summary is grounded in secondary research from publicly available regulatory, policy, scientific, and industry sources, including FDA, EMA, MHRA, WHO, ICH, OECD, national health agencies, public health procurement documents, inspection guidance, scientific publications, company filings, investor disclosures, and peer-reviewed literature. The analysis emphasizes verifiable structural indicators such as manufacturing capability, regulatory frameworks, inspection expectations, supply chain trends, therapeutic modality requirements, and documented policy priorities.

Insights are synthesized through a market-mapping approach that compares regions, strategic groups, and countries across demand drivers, compliance maturity, outsourcing intensity, technology adoption, manufacturing specialization, and supply resilience. The methodology avoids unsupported market-size, market-share, or forecasting claims and uses only evidence-based directional insights supported by identifiable public sources.

Conclusion

The healthcare CDMO market is entering a more strategic phase defined by technical complexity, quality expectations, regional diversification, and digital transformation. Sponsors are relying on CDMOs not only to reduce fixed manufacturing investment but also to access specialized expertise, accelerate development timelines, support regulatory readiness, and protect supply continuity.

The strongest CDMO performers will combine regulatory credibility, flexible capacity, AI-enabled process intelligence, robust quality systems, skilled technical teams, and global network resilience. As biologics, sterile products, advanced therapies, vaccines, high-potency compounds, and complex generics expand, trusted CDMO partnerships will remain essential to competitive healthcare manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Healthcare Contract Development & Manufacturing Organization Market, by Service Offering

  • 7.1. Contract Development Services
    • 7.1.1. Clinical Development
      • 7.1.1.1. Clinical Trials Support
      • 7.1.1.2. Regulatory Support
    • 7.1.2. Preclinical Development
      • 7.1.2.1. In Vitro & In Vivo Studies
      • 7.1.2.2. Toxicology Studies
    • 7.1.3. Process Development
  • 7.2. Contract Manufacturing Services
    • 7.2.1. API Manufacturing
    • 7.2.2. Finished Dosage Form Manufacturing (FDF)
    • 7.2.3. Medical Device Manufacturing
    • 7.2.4. Packaging & Labeling

8. Healthcare Contract Development & Manufacturing Organization Market, by Molecule Type

  • 8.1. Large Molecules
    • 8.1.1. Monoclonal Antibodies
    • 8.1.2. Recombinant Proteins
    • 8.1.3. Vaccines
  • 8.2. Small Molecules

9. Healthcare Contract Development & Manufacturing Organization Market, by Dosage Form

  • 9.1. Liquid Dosage Forms
  • 9.2. Semi-Solid Dosage Forms
  • 9.3. Solid Dosage Forms

10. Healthcare Contract Development & Manufacturing Organization Market, by Application

  • 10.1. Generic Drugs
  • 10.2. Medical Devices
  • 10.3. Patented Drugs

11. Healthcare Contract Development & Manufacturing Organization Market, by Therapeutic Area

  • 11.1. Cardiology
  • 11.2. Immunology
  • 11.3. Infectious Disease
  • 11.4. Metabolic Disorders
  • 11.5. Neurology
  • 11.6. Oncology

12. Healthcare Contract Development & Manufacturing Organization Market, by End User

  • 12.1. Academic & Research Institutions
  • 12.2. Biotechnology Companies
  • 12.3. Generic Drug Manufacturers
  • 12.4. Medical Device Companies
  • 12.5. Pharmaceutical Companies
    • 12.5.1. Big Pharmaceutical Companies
    • 12.5.2. Small & Medium-sized Pharmaceutical Companies

13. Healthcare Contract Development & Manufacturing Organization Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Healthcare Contract Development & Manufacturing Organization Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Healthcare Contract Development & Manufacturing Organization Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Baxter International, Inc.
  • 17.2. Boehringer Ingelheim International GmbH
  • 17.3. Cambrex Corporation
  • 17.4. Catalent Inc.
  • 17.5. Charles River Laboratories International, Inc.
  • 17.6. Corden Pharma International GmbH
  • 17.7. Curia Global, Inc.
  • 17.8. Eurofins Scientific SE
  • 17.9. EVER company group
  • 17.10. Evonik Industries AG
  • 17.11. FUJIFILM Diosynth Biotechnologies
  • 17.12. Jabil, Inc.
  • 17.13. Lonza Group AG
  • 17.14. MedPharm Ltd.
  • 17.15. Merck KGaA
  • 17.16. NextPharma GmbH
  • 17.17. Piramal Group
  • 17.18. Porton Pharma Solutions Ltd
  • 17.19. Recipharm AB
  • 17.20. Samsung Biologics
  • 17.21. Sanmina Corporation
  • 17.22. Siegfried Holding AG
  • 17.23. Siegfried-Group
  • 17.24. Thermo Fisher Scientific, Inc.
  • 17.25. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL API MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL API MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL API MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PACKAGING & LABELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PACKAGING & LABELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PACKAGING & LABELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LARGE MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LARGE MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LARGE MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MEDICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MEDICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MEDICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PATENTED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PATENTED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PATENTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 212. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 214. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 216. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 217. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 220. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 221. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 251. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 253. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 255. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 256. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 259. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 260. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 264. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 266. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 268. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 269. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 270. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 272. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 273. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 275. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)

TA